Mechanism of action and clinical development of platelet thrombin receptor antagonists

References

• Davi G, Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med.357(24), 2482–2494 (2007).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ. J.74(4), 597–607 (2010).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366(9497), 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med.352(12), 1179–1189 (2005).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357(20), 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361(11), 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA288(19), 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Brummel KE, Paradis SG, Butenas S et al. Thrombin functions during tissue factor-induced blood coagulation. Blood100(1), 148–152 (2002).
   PubMed Web of Science ®Google Scholar
• Davey MG, Lüscher EF. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature216(5118), 857–858 (1967).
   PubMed Web of Science ®Google Scholar
• Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res.100(9), 1261–1275 (2007).
   PubMed Web of Science ®Google Scholar
• Coughlin SR. How the protease thrombin talks to cells. Proc. Natl Acad. Sci. USA96(20), 11023–11027 (1999).
   PubMed Web of Science ®Google Scholar
• Coughlin SR. Protease-activated receptors in vascular biology. Thromb. Haemost.86(1), 298–307 (2001).
   PubMed Web of Science ®Google Scholar
• Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost.3(8), 1800–1814 (2005).
   PubMed Web of Science ®Google Scholar
• Coughlin SR. Thrombin signalling and proteaseactivated receptors. Nature407(6801), 258–264 (2000).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur. Heart J.31(1), 17–28 (2010).
   PubMed Web of Science ®Google Scholar
• Al-Ani B, Saifeddine M, Hollenberg MD. Detection of functional receptors for the proteinase-activated receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle. Can. J. Physiol. Pharmacol.73(8), 1203–1207 (1995).
   PubMed Web of Science ®Google Scholar
• Ishihara H, Connolly AJ, Zeng D et al. Protease activated receptor-3 is a second thrombin receptor in humans. Nature386(6624), 502–506 (1997).
   PubMed Web of Science ®Google Scholar
• Cupit LD, Schmidt VA, Gnatenko DV, Bahou WF. Expression of protease activated receptor 3 (PAR3) is upregulated by induction of megakaryocyte phenotype in human erythroleukemia (HEL) cells. Exp. Hematol.32(10), 991–999 (2004).
   PubMed Web of Science ®Google Scholar
• Kahn ML, Zheng YW, Huang W et al. A dual thrombin receptor system for platelet activation. Nature394(6694), 690–694 (1998).
   PubMed Web of Science ®Google Scholar
• Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc. Natl Acad. Sci. USA9(20), 9208–9212 (1994).
   Google Scholar
• Chackalamannil S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J. Med. Chem.49(18), 5389–5403 (2006).
   PubMed Web of Science ®Google Scholar
• Shah R. Protease-activated receptors in cardiovascular health and diseases. Am. Heart J.157(2), 253–262 (2009).
   PubMed Web of Science ®Google Scholar
• Xu W-f, Andersen H, Whitmore TE et al. Cloning and characterization of human protease-activated receptor 4. Proc. Natl Acad. Sci. USA95(12), 6642–6646 (1998).
   PubMed Web of Science ®Google Scholar
• Tesfamariam B. Thrombin receptor-mediated vascular relaxation differentiated by a receptor antagonist and desensitization. Am. J. Physiol.267(5 Pt 2), H1962–H1967 (1994).
   Google Scholar
• Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium dependent and endothelium independent coronary vascular effects in dogs. J. Cardiovasc. Pharmacol.22(4), 609–616 (1993).
   PubMed Web of Science ®Google Scholar
• Zimmerman GA, Elstad MR, Lorant DE et al. Platelet-activating factor (PAF): signalling and adhesion in cell–cell interactions. Adv. Exp. Med. Biol.416, 297–304 (1996).
   PubMedGoogle Scholar
• Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J. Immunol.160(10), 5130–5135 (1998).
   PubMed Web of Science ®Google Scholar
• Chintala MS, Chiu PJ, Bernadino V et al. Disparate effects of thrombin receptor activating peptide on platelets and peripheral vasculature in rats. Eur. J. Pharmacol.349(2–3), 237–243 (1998).
   PubMed Web of Science ®Google Scholar
• Chackalamannil S, Xia Y, Greenlee WJ et al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J. Med. Chem.48(19), 5884–5887 (2005).
   PubMed Web of Science ®Google Scholar
• Chintala M, Ahn HS, Foster C et al. Antithrombotic effects of SCH 205831: a potent, selective and orally active antagonist of the PAR-1 thrombin receptor. J. Thromb. Haemost.3(Suppl. 1), 286 (2005).
   Google Scholar
• Chintala M, Kurowski S, Vemulapalli S et al. Efficacy of SCH 602539, a selective thrombin receptor antagonist alone and in combination with cangrelor in a Folts model of thrombosis in anesthetized monkeys. Eur. Heart J.28(Suppl. 1), 188 (2007).
   Google Scholar
• Chackalamannil S, Wang Y, Greenlee WJ et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J. Med. Chem.51(11), 3061–3064 (2008).
   PubMed Web of Science ®Google Scholar
• Chintala M, Vemulapalli S, Kurowski S et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Arterioscl. Thromb. Vasc. Biol.28, e138–e139 (2008).
   Web of Science ®Google Scholar
• Chackalamannil S, Davies RJ, Asberom T Doller D, Leone D. A highly efficient total synthesis of (+)-himbacine. J. Am. Chem. Soc.40(118), 9812–9813 (1996).
   Google Scholar
• Doller D, Chackalamannil S, Czarniecki M, McQuade R, Ruperto V. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg. Med. Chem. Lett.9(6), 901–906 (1999).
   PubMed Web of Science ®Google Scholar
• The TRACER Exective and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial: study design and rationale. Am. Heart J.158(3), 327–334 (2009).
   PubMed Web of Science ®Google Scholar
• Morrow DA, Scirica BM, Fox KA et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA2P)-TIMI 50 trial. Am. Heart J.158(3), 335–341 (2009).
   PubMed Web of Science ®Google Scholar
• Oestreich J. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Curr. Opin. Invest. Drugs10(9), 988–996 (2009).
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Reydeman L, Fales RR et al. Pharmacodynamics, and pharmacokinetics of novel protease-activated receptor antagonist SCH 530348. Circulation112(Suppl.), 32 (2005).
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Tiessen R, Van Vliet AA, Fales RR, Keller R, Cutler DL. Safety and tolerability of SCH 530348, a novel antiplatelet agent, after single and multiple oral dosing in healthy subjects. Eur. Heart J.29(Suppl.), 201, P1340 (2008).
   Google Scholar
• Reyderman L, Kosoglou T, Kasserra C et al. Lack of ethnic differences in the pharmacodynamics (PD) and pharmacokinetics (PK) of SCH 530348, a novel oral antiplatelet agent, in Japanese and Caucasian subjects. Clin. Pharmacol. Ther.85(Suppl. 1), S21, PI-41 (2009).
   Google Scholar
• Kosoglou T, Reyderman L, Kasserra C et al. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects. Clin. Pharmacol. Ther.83(Suppl. 1), S55 (2008).
   Google Scholar
• Becker RC, Moliterno DJ, Jennings LK et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled Phase II study. Lancet373(9667), 919–928 (2009).
   PubMed Web of Science ®Google Scholar
• Jennings LK, Earhart A, Becker RC, Reyderman L, Veltri E, Harrington RA. Thrombin receptor antagonist (TRA; SCH530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokinetics. Presented at: American Heart Association Scientific Sessions. Orlando, FL, USA, 4–7 November 2007.
   Google Scholar
• Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P. Phase II trial of the novel antiplatelet agent, SCH 530348, in Japanese patients with non-ST segment elevation acute coronary syndromes (NSTE ACS). Eur. Heart J.29(Suppl.), 829, P4767 (2008).
   PubMedGoogle Scholar
• Shinohara Y, Goto S, Shimizu K, Jensen P. A Phase II safety study of novel antiplatelet agent, SCH 530348, in Japanese patients with prior ischemic stroke. Int. J. Stroke3(Suppl. 1), 139, PO101–PO193 (2008).
   Google Scholar
• Serebruany VL, Kogushi M, Dastros-Pitei D Flather M, Bhatt DL. The in vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb. Haemost.102(1), 111–119 (2009).
   PubMed Web of Science ®Google Scholar
• Kogushi M, Kobayashi H, Matsuoka T et al. Antithrombotic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs. Circulation108(Suppl. IV), 280 (2003).
   Google Scholar
• Kai Y, Hirano K, Maeda Y, Nishimura J, Sasaki T, Kanaide H. Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke38(12), 3259–3265 (2007).
   PubMed Web of Science ®Google Scholar
• Kogushi M, Yokohama H, Kitamura S, Hishinuma I. Effects of E5555, a protease activated receptor-1 antagonist, on the inflammatory markers in vitro. J. Thromb. Haemost.5(Suppl.), 059 (2007).
   Google Scholar
• Marion A, Reyes J, Chen H, Wittek A. Safety, pharmacokinetics and pharmacodynamics of ascending multiple oral doses of a new protease activated receptor-1 inhibitor in healthy volunteers. Presented at: American College of Clinical Pharmacology 35th Annual Meeting. Cambridge, MA, USA, 17–19 September 2006.
   Google Scholar
• Takeuchi M, Kageyama M, Kitamura S, Hagino R, Ozawa H, Tanaka H. Pharmacodynamics and safety of a novel protease activated receptor-1 antagonist E5555 for healthy volunteers. Eur. Heart J.28(Suppl.), 14 (2007).
   Google Scholar